GSK PLC (GSK)
44.52
+0.96 (+2.20%)
USD |
NYSE |
May 20, 16:00
44.50
-0.02 (-0.04%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 113.17B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 19.58% |
| Valuation | |
| PE Ratio | 16.13 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.265 |
| Price to Book Value | 5.324 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.3496 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 2.060 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 32.61% |
News
Headline
Wire
Time (ET)
SA Breaking News
05/13 09:04
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 07/28/2022* | -- | Results | Q2 2022 | -- | 0.73 | -- | |
| 04/27/2022 | -- | Results | Q1 2022 | 0.83 | 0.76 | 8.32% | |
| 02/09/2022 | -- | Results | Q4 2021 | 0.69 | 0.65 | 7.18% | |
| 10/27/2021 | -- | Results | Q3 2021 | 1.01 | 0.81 | 23.90% | |
| 07/28/2021 | -- | Results | Q2 2021 | 0.78 | 0.33 | 135.8% | |
| 04/28/2021 | -- | Results | Q1 2021 | 0.64 | 0.48 | 33.31% | |
| 02/03/2021 | -- | Results | Q4 2020 | 0.64 | 0.48 | 32.00% | |
| 10/28/2020 | -- | Results | Q3 2020 | 0.92 | 0.86 | 7.87% |
*Estimated Date/Time
Earnings
Profile
Edit
| In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. |
| URL | https://www.gsk.com |
| Investor Relations URL | https://www.gsk.com/en-gb/investors/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jul. 28, 2022 (est.) |
| Last Earnings Release | Apr. 27, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 19, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 2.166 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 3.369 |
| Yield to Sector | 2.323 |
| Yield to Industry | 1.329 |
| Last Dividend Amt. | 0.3496 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | May. 19, 2022 |
| Yield (TTM) | 4.46% |
| Forward Yield | 4.46% |
| Payout Ratio | 78.35% |
| Cash Payout Ratio | 57.37% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 20, 2022.
Fundamentals
| Revenue (TTM) | 49.79B |
| Total Expenses (TTM) | 39.16B |
| Net Income (TTM) | 6.988B |
| Total Assets (Quarterly) | 117.82B |
| Total Liabilities (Quarterly) | 88.09B |
| Shareholders Equity (Quarterly) | 21.26B |
| Cash from Operations (TTM) | 13.89B |
| Cash from Investing (TTM) | -7.199B |
| Cash from Financing (TTM) | 2.153B |
Ratings
Profile
Edit
| In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. |
| URL | https://www.gsk.com |
| Investor Relations URL | https://www.gsk.com/en-gb/investors/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jul. 28, 2022 (est.) |
| Last Earnings Release | Apr. 27, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 19, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| PPH | 20.04M USD | 4.67% |
| CIG21506 | 115.42M USD | 4.16% |
| VIRS | 207651.0 USD | 3.78% |
| DOXGX | 2.580B USD | 2.61% |
| GCOW | 8.258M USD | 1.94% |
| DOXBX | 297.11M USD | 1.87% |
| PAIGX | 172.12M USD | 1.41% |
| FGIKX | 87.07M USD | 1.06% |
| TTAI | 570636.0 USD | 1.02% |
| MNCSX | 30.67M USD | 0.90% |
| RODM | 12.40M USD | 0.82% |
| AVDE | 6.683M USD | 0.49% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| GSK Tweets |